Mabion S.A. - Asset Resilience Ratio

Latest as of September 2020: 0.03%

Mabion S.A. (MAB) has an Asset Resilience Ratio of 0.03% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Mabion S.A. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

zł23.00K

≈ $6.33K USD Cash + Short-term Investments

Total Assets

zł80.62 Million

≈ $22.19 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2018)

This chart shows how Mabion S.A.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MAB current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Mabion S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read MAB liabilities breakdown for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	zł0.00	0%
Short-term Investments	zł23.00K	0.03%
Total Liquid Assets	zł23.00K	0.03%

Asset Resilience Insights

Limited Liquidity: Mabion S.A. maintains only 0.03% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Mabion S.A. Industry Peers by Asset Resilience Ratio

Compare Mabion S.A.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Genscript Biotech Corporation F:G51	Biotechnology	13.79%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
89bio Inc NASDAQ:ETNB	Biotechnology	71.60%
Pacific Shuanglin Bio pharmacy Co Ltd SHE:000403	Biotechnology	2.66%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%

Annual Asset Resilience Ratio for Mabion S.A. (2012–2018)

The table below shows the annual Asset Resilience Ratio data for Mabion S.A..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2018-12-31	0.07%	zł108.00K ≈ $29.72K	zł144.72 Million ≈ $39.83 Million	-4.62pp
2014-12-31	4.69%	zł69.53 Million ≈ $19.14 Million	zł1.48 Billion ≈ $407.64 Million	-0.08pp
2013-12-31	4.78%	zł36.06 Million ≈ $9.92 Million	zł754.68 Million ≈ $207.70 Million	-6.57pp
2012-12-31	11.34%	zł449.85 Million ≈ $123.81 Million	zł3.97 Billion ≈ $1.09 Billion	--

pp = percentage points

About Mabion S.A.

WAR:MAB Poland Biotechnology

Market Cap

$33.85 Million

zł123.00 Million PLN

Market Cap Rank

#23463 Global

#224 in Poland

Share Price

zł7.61

Change (1 day)

-2.93%

52-Week Range

zł6.82 - zł9.63

All Time High

zł134.60